At what enterprise value was AFFIDEA acquired in 2022?

During the acquisition of AFFIDEA by GROUPE BRUXELLES LAMBERT in 2022, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of AFFIDEA when it was acquired by GROUPE BRUXELLES LAMBERT?

The estimated EV/EBITDA multiple for AFFIDEA is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was AFFIDEA acquired by GROUPE BRUXELLES LAMBERT?

AFFIDEA was acquired by GROUPE BRUXELLES LAMBERT in 2022.

What was the revenue of AFFIDEA at the time of the deal?

The revenue of AFFIDEA at the time of the deal is estimated to be in the range of 450M - 900M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of AFFIDEA during the acquisition?

AFFIDEA's EBITDA is estimated to be in the range of 100M - 200M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the AFFIDEA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the AFFIDEA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://affidea.ch/fr/actualites/affidea-groupe-bruxelles-lambert/

← DATABASE

Home Database Healthcare & PharmaAFFIDEA

04/2022

AFFIDEA acquired by GROUPE BRUXELLES LAMBERT

NETHERLANDS Health Providers / Outpatient Care / Radiology EV 1b - 4b EUR

Context

The Brussels Lambert Group (GBL) has finalized the acquisition of a majority stake in Affidea, the European leader in diagnostic imaging and outpatient care, from B-FLEXION (family office), which is exiting the investment after eight years. The transaction is structured as a secondary LBO in which the current management team has reinvested a significant portion of its proceeds alongside GBL to ensure alignment of interests. This buyout marks a major step in the strategic rotation of GBL's portfolio, significantly increasing its exposure to private assets at the expense of its historic listed holdings.

AFFIDEA, which reported an EBITDA margin of in 2021, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 1991, Affidea is Europe's leading provider of diagnostic imaging, outpatient care, and oncology services. The group operates 320 centers in 15 countries, welcoming more than 10 million patients per year. It is recognized for its clinical excellence (more than 50% of its centers are “Eurosafe Star” certified in Europe).

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2021

2020

Similar deals in Health Providers

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
06/2022	EURAZEO	SEVETYS	FRANCE	Vet Clinics
06/2022	TRITON PARTNERS	ESPERI CARE	FINLAND	Nursing Homes
02/2022	MEINE RADIOLOGIE	ALERIS - RADIOLOGY	SWEDEN	Radiology
01/2022	WREN HOUSE	VOYAGE CARE	UNITED KINGDOM	Nursing Homes
12/2021	VIVALTO PARTNERS / IK PARTNERS / MACSF / ARKEA CAPITAL / BNP PARIBAS DEVELOPPEMENT	VIVALTO SANTÉ	FRANCE	Clinics / Hospitals
12/2021	RAMSAY HEALTH CARE	ELYSIUM HEALTHCARE	UNITED KINGDOM	Clinics / Hospitals
11/2021	CERBA HEALTHCARE	LABEXA	FRANCE	Labs (Biology)
10/2021	THE CRANEMERE GROUP	OUTPATIENT IMAGING AFFILIATES	UNITED STATES	Radiology
10/2021	IVC EVIDENSIA	VETONE	FRANCE	Vet Clinics
10/2021	ARES / BPIFRANCE	POINT VISION	FRANCE	Ophthalmology

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 450M - 900M EUR

EBITDA range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of AFFIDEA by GROUPE BRUXELLES LAMBERT are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: affidea

Acquirer: groupe bruxelles lambert